에 대한 최신 뉴스 Trip.com Group (NASDAQ:TCOM) 주식

Trip.com Group

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from its online platform, but the company also maintains offline call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

buildings-673087

News

BABA

TCOM

수요일(9일) 오후 도널드 트럼프 대통령이 미국의 무역 조치에 보복하지 않은 국가에 대한 추가 관세 90일 유예를 발표하면서 대형 중국 기업 주식을 추종하는 iShares China Large-Cap ETF(NASDAQ:FXI)가 반등했다.

중국 제외한 관세 유예 발표...알리바바, JD닷컴 및 대형 중국 주식 상황은?

MicroStrategy Incorporated (MSTR)

Equities

Large Cap

Movers

Trading Ideas

$BTC

ESLT

MRNA

MSTR

OKTA

지난주 가장 좋은 성과를 보인 대형주 10개는 다음과 같다.

옥타·모더나·스트레티지 등 지난주 급등한 대형주 10종목 (3월 3일~7일)

Inscription,Investment.,China,Flag,,With,The,Financial,Data,In,The

Opinion

FINV

많은 국가가 2025년까지 지출을 줄이려고 노력하고 있지만, 주목할 만한 국가 중 한 곳은 바로 중국이다. 중국 정부는 침체된 경제를 부양하기 위해 일련의 경기 부양책을 약속해 왔으며, 지난주 은행 부문에 550억 달러(4,000억 위안) 이상을 투입하겠다고 발표하면서 이러한 금전적 약속 중 하나가 이행되었다.알리바바 JD닷컴 핀볼루션 트립닷컴

중국의 대규모 부양책 속 매수할 만한 주식 4종목

Trip.com Group Limited - American Depositary Shares

Trip.com Group Ltd

Apple's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44751387/apple-analyst-slashes-price-forecast-on-weak-iphone-demand-ai-revenue-despite-less-tariff-risk">biggest iPhone headache</a> might not be a chip shortage — it's tariffs. President Donald Trump's aggressive new round of China tariffs has temporarily spared electronics like smartphones and laptops, but that grace period is short-lived.&nbsp;
Commerce Secretary Howard Lutnick on Sunday told <a href="https://abcnews.go.com/Politics/commerce-secretary-lutnick-tariff-exemptions-electronics-temporary/story?id=120752319">ABC's "This Week"</a> that Apple and other tech companies should expect new semiconductor-specific tariffs "in probably a month or two."&nbsp;
Apple's dependence on China is massive. Roughly 90% of iPhones are made there. As <a href="https://www.theguardian.com/us-news/2025/apr/11/iphone-apple-trump-tariffs-tech-us-china">The Guardian reports</a>, if tariffs stick and Apple doesn't shift production, the iPhone 16 Pro Max could jump from $1,199 to $2,150 — <a href="https://www.benzinga.com/markets/equities/25/04/44728758/trumps-tariffs-could-push-apple-iphone-prices-to-a-staggering-3500-says-top-analyst">or even $3,500</a> if production were forced into the U.S.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Ironically, this was a debate 14 years ago.
At a 2011 Silicon Valley dinner with then-President Barack Obama, Apple CEO <a href="https://www.benzinga.com/personal-finance/25/04/44780772/bill-gates-said-its-a-gross-oversimplification-to-compare-elon-musk-to-genius-steve-jobs-you-wouldnt-walk-into-a-room-and-confu">Steve Jobs </a>gave a blunt answer when asked what it would take to make iPhones in America: "Those jobs aren't coming back." That quote, reported by <a href="https://www.nytimes.com/2012/01/22/business/apple-america-and-a-squeezed-middle-class.html">The New York Times</a>, captured the stark reality of globalized manufacturing.&nbsp;
It wasn't just about labor costs. At the time of the 2011 article, experts estimated that paying American wages would only add about $65 to each iPhone.
The real issue was China's supply chain dominance. "You need a million screws? That factory is a block away," a former Apple executive told the Times.
In that same dinner, Jobs said that Apple could potentially bring some high-skill manufacturing to the U.S. if the government helped train engineers. But he was clear: America didn't have the mid-level engineering workforce or production speed needed to compete.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Current Apple CEO Tim Cook has tried to soften that stance. Apple in Februay <a href="https://www.apple.com/newsroom/2025/02/apple-will-spend-more-than-500-billion-usd-in-the-us-over-the-next-four-years/">announced</a> plans to invest $500 billion in the U.S. over four years, building a new factory in Texas and expanding teams across 10 states. But most iPhones are still made abroad.
Even back in 2012, Cook pledged $100 million to build some Mac computers in the U.S. While this move garnered attention, analysts viewed it as a strategic decision rather than a significant shift in Apple's manufacturing strategy. Tom Dinges, a senior supply chain analyst at IHS, <a href="https://www.wired.com/2012/12/apple-insourcing/">told Wired</a> the impact would be minimal across Apple's global operations.
But more than a decade later, the conditions Cook once hedged against may be catching up.
Apple has started ramping up production in India, aiming for 25 million units this year, but China remains its manufacturing heart. As Trump pushes tariffs, Apple may be forced to test Jobs' theory — whether those jobs really are gone for good, or whether a $3,500 iPhone is what it takes to bring them home.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

AAPL

Steve Jobs Said 14 Years Ago iPhones Would Never Be Made In The U.S.: 'Those Jobs Aren't Coming Back'—Now Tariffs Could Lift Price To $3,500

Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) has outperformed the market over the past 20 years by 2.48% on an annualized basis producing an average annual return of 10.38%. Currently, Micron Technology has a market capitalization of $77.11 billion. 
Buying $1000 In MU: If an investor had bought $1000 of MU stock 20 years ago, it would be worth $7,181.63 today based on a price of $69.00 for MU at the time of writing.
<h3>Micron Technology's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744929011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Micron Technology 20 Years Ago Would Be Worth This Much Today

Texas Pacific Land (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) has outperformed the market over the past 10 years by 44.19% on an annualized basis producing an average annual return of 53.78%. Currently, Texas Pacific Land has a market capitalization of $29.85 billion. 
Buying $100 In TPL: If an investor had bought $100 of TPL stock 10 years ago, it would be worth $7,330.05 today based on a price of $1298.64 for TPL at the time of writing.
<h3>Texas Pacific Land's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744928110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Texas Pacific Land 10 Years Ago Would Be Worth This Much Today

Spring offers an ideal opportunity to refresh financial health. Just as decluttering a home brings clarity and calm, conducting a financial spring cleaning can help gain control, reduce stress and set the stage for future success. Here are key<a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854372/gold-hits-new-record-highs-as-safe-haven-demand-climbs-2-ways-to-invest"> steps to consider:</a>
<h1 class="wp-block-heading">Review Budget and Spending</h1>
Begin by revisiting the household budget. Track expenses over recent months to reveal unnecessary or impulsive purchases and adjust the budget to align with current financial goals — such as saving for a vacation, paying down debt or building an emergency fund.&nbsp;
Credit Karma, an app from Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), can organize each transaction by category and track spending habits and identify leftover funds available for investing or saving.&nbsp;
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;&nbsp;</a>
<h1 class="wp-block-heading">Tackle Debt Strategically</h1>
Addressing debt is an essential part of financial spring cleaning. Listing all debts, including interest rates and minimum payments, can help prioritize high-interest debts like credit cards. Paying off high-interest debt quickly helps save money and can enhance credit scores.
<h1 class="wp-block-heading">Optimize Savings</h1>
Evaluate savings accounts and emergency funds often, but at least once a year. Ideally, an emergency fund should cover three to six months of expenses or more. Automatic transfers to savings accounts can facilitate the steady growth of financial reserves.&nbsp;
Acorns offers<a href="https://www.acorns.com/"> an app </a>that can automatically transfer small amounts from a checking account into a savings account to build an emergency fund over time.&nbsp;
<h1 class="wp-block-heading">Check Subscriptions and Bills</h1>
Reviewing and canceling unused subscriptions, as well as negotiating bills such as cable, internet or insurance, can lead to significant monthly savings. The savings can then be redirected toward more important financial objectives.&nbsp;
Rocket Money, an app from Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), can help identify unused or duplicate subscriptions and even help to cancel them.&nbsp;
<h1 class="wp-block-heading">Plan for the Future</h1>
Review retirement accounts and investment portfolios to ensure that asset allocation matches risk tolerance and time horizons. For those who have yet to begin investing, spring presents an excellent opportunity to start.
Some online brokerages, like Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Webull Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>), offer retirement investment accounts and easy-to-learn apps.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

BULL

HOOD

INTU

'Spring Clean' Your Personal Finances With These Apps

<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/fda-fires-most-negotiators-pharma-user-fee-talks-sources-say-2025-04-17/">https://www.reuters.com/business/healthcare-pharmaceuticals/fda-fires-most-negotiators-pharma-user-fee-talks-sources-say-2025-04-17/</a>

Biotech

General

'FDA Fires Most Negotiators For Pharma User Fee Talks, Sources Say' - Reuters Exclusive

In the latest quarter, 10 analysts provided ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $16.5, a high estimate of $29.00, and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.79%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927268_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $14.00&#x7C;$18.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $20.00&#x7C;$24.00 &#x7C; 
&#x7C;Dave Weiner &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $12.50&#x7C;$11.50 &#x7C; 
&#x7C;Dave Weiner &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $11.50&#x7C;$14.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $11.00&#x7C;$13.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $19.00&#x7C;$27.00 &#x7C; 
&#x7C;Lu Li &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $16.00&#x7C;$18.00 &#x7C; 
&#x7C;John Wilkin &#x7C;Craig-Hallum &#x7C;Announces &#x7C;Buy &#x7C; $29.00&#x7C;- &#x7C; 
&#x7C;John Peterson &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$24.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$29.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Myriad Genetics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Myriad Genetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Myriad Genetics's Background</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Myriad Genetics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Myriad Genetics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.12%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -20.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE excels beyond industry benchmarks, reaching -5.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MYGN

Demystifying Myriad Genetics: Insights From 10 Analyst Reviews

8 analysts have shared their evaluations of Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Astera Labs and provided 12-month price targets. The average target is $115.38, accompanied by a high estimate of $142.00 and a low estimate of $82.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.12%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927261_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Astera Labs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$150.00 &#x7C; 
&#x7C;Atif Malik &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Srini Pajjuri &#x7C;Raymond James &#x7C;Announces &#x7C;Outperform &#x7C; $82.00&#x7C;- &#x7C; 
&#x7C;Richard Shannon &#x7C;Craig-Hallum &#x7C;Raises &#x7C;Buy &#x7C; $125.00&#x7C;$105.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $140.00&#x7C;$140.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $114.00&#x7C;$142.00 &#x7C; 
&#x7C;Gus Richard &#x7C;Northland Capital Markets&#x7C;Maintains &#x7C;Outperform &#x7C; $120.00&#x7C;$120.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $142.00&#x7C;$142.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Astera Labs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Astera Labs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Astera Labs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Astera Labs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Astera Labs analyst ratings.</a>
<h2>Delving into Astera Labs's Background</h2>
Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.
<h3>Financial Milestones: Astera Labs's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Astera Labs's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 179.32%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Astera Labs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 17.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Astera Labs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Astera Labs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.43%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Astera Labs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAB

8 Analysts Have This To Say About Astera Labs

In the preceding three months, 8 analysts have released ratings for C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for C3.ai, revealing an average target of $23.62, a high estimate of $30.00, and a low estimate of $17.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 27.05%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927251_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive C3.ai. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eric Heath &#x7C;Keybanc &#x7C;Lowers &#x7C;Underweight &#x7C; $17.00&#x7C;$21.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $20.00&#x7C;$30.00 &#x7C; 
&#x7C;Gil Luria &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$25.00 &#x7C; 
&#x7C;Kingsley Crane &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $30.00&#x7C;$40.00 &#x7C; 
&#x7C;Gil Luria &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$40.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Lowers &#x7C;Underweight &#x7C; $21.00&#x7C;$29.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $30.00&#x7C;$32.00 &#x7C; 
&#x7C;Arvind Ramnani &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $28.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to C3.ai. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C3.ai compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of C3.ai's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on C3.ai analyst ratings.</a>
<h2>Discovering C3.ai: A Closer Look</h2>
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
<h3>Unraveling the Financial Story of C3.ai</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: C3.ai's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 26.0%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: C3.ai's net margin excels beyond industry benchmarks, reaching -81.19%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): C3.ai's ROE stands out, surpassing industry averages. With an impressive ROE of -9.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): C3.ai's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: C3.ai's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying C3.ai: Insights From 8 Analyst Reviews

10 analysts have shared their evaluations of Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Welltower and provided 12-month price targets. The average target is $173.6, accompanied by a high estimate of $242.00 and a low estimate of $144.00. Observing a 9.18% increase, the current average has risen from the previous average price target of $159.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927239_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Welltower. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;John Kilichowski &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Overweight &#x7C; $158.00&#x7C;$158.00 &#x7C; 
&#x7C;Omotayo Okusanya &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $170.00&#x7C;$141.00 &#x7C; 
&#x7C;John Kilichowski &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $158.00&#x7C;$140.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $166.00&#x7C;$165.00 &#x7C; 
&#x7C;Steve Sakwa &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;In-Line &#x7C; $145.00&#x7C;$144.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $165.00&#x7C;$144.00 &#x7C; 
&#x7C;Joshua Dennerlein &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $242.00&#x7C;$221.00 &#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Raises &#x7C;Outperform &#x7C; $167.00&#x7C;$145.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $144.00&#x7C;$142.00 &#x7C; 
&#x7C;Joshua Dennerlein &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $221.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Welltower. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Welltower compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Welltower's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Welltower's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WELL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Welltower analyst ratings.</a>
<h2>Get to Know Welltower Better</h2>
Welltower owns a diversified healthcare portfolio of 2,271 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in both Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
<h3>Financial Milestones: Welltower's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Welltower displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 29.18%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Welltower's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.39%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Welltower's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WELL

Breaking Down Welltower: 10 Analysts Share Their Views

19 analysts have expressed a variety of opinions on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.74, a high estimate of $45.00, and a low estimate of $29.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $36.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927228_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Exelixis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Derek Archila &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$25.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;David Lebowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $45.00&#x7C;$38.00 &#x7C; 
&#x7C;Michael Schmidt &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Stephen Willey &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $36.00&#x7C;$30.00 &#x7C; 
&#x7C;Joseph Catanzaro &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $38.00&#x7C;$37.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $34.00&#x7C;$30.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Asthika Goonewardene&#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $43.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Jefferson Harralson &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$30.00 &#x7C; 
&#x7C;Jay Olson &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Perform &#x7C; $33.00&#x7C;$41.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exelixis's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 6.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

In the current market session, Mr. Cooper Gr Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) stock price is at $111.21, after a 1.34% drop. However, over the past month, the company's stock spiked by 5.32%, and in the past year, by 43.40%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744927219_0.png" alt="Past Year Chart" />

<h3>Mr. Cooper Gr P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Mr. Cooper Gr has a lower P/E than the aggregate P/E of 14.0 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744927219_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

COOP

P/E Ratio Insights for Mr. Cooper Gr

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 20.12% on an annualized basis producing an average annual return of 34.15%. Currently, Liberty Energy has a market capitalization of $1.96 billion. 
Buying $1000 In LBRT: If an investor had bought $1000 of LBRT stock 5 years ago, it would be worth $4,209.06 today based on a price of $12.08 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744927219_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

Here's How Much $1000 Invested In Liberty Energy 5 Years Ago Would Be Worth Today

Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.33, along with a high estimate of $32.00 and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.59%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927217_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Reynolds Consumer Prods is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $26.00&#x7C;$29.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $24.00&#x7C;$26.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $27.00&#x7C;$31.00 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $30.00&#x7C;$31.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $30.00&#x7C;$32.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $31.00&#x7C;$32.00 &#x7C; 
&#x7C;Robert Ottenstein &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $30.00&#x7C;$33.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $32.00&#x7C;$32.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reynolds Consumer Prods. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Reynolds Consumer Prods compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Reynolds Consumer Prods's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Reynolds Consumer Prods's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/REYN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Reynolds Consumer Prods analyst ratings.</a>
<h2>Delving into Reynolds Consumer Prods's Background</h2>
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.
<h3>Reynolds Consumer Prods's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Reynolds Consumer Prods showcased positive performance, achieving a revenue growth rate of 1.39% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Reynolds Consumer Prods's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.75%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.49%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Reynolds Consumer Prods's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.83.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REYN

Assessing Reynolds Consumer Prods: Insights From 9 Financial Analysts

When Chinese AI lab Deepseek released a state-of-the-art large language model for free, it marked a turning point in enterprise AI strategy — especially for financial institutions. The move underscored a broader shift: the emergence of open-source AI as a serious contender to proprietary offerings.
While open-source tools have long been foundational to developer ecosystems, their influence rarely extended into core infrastructure. That changed when companies like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) began publishing foundational models freely, echoing Google's Android strategy — build the ecosystem now, monetize later.
The trend is accelerating. Deepseek's release made waves for several reasons:
<ul>
<li>State-of-the-art models are now widely available at no cost.</li>
<li>Training these models has become more economically feasible.</li>
<li>Open-source distribution can accelerate adoption — Deepseek's app reportedly reached the top of mobile app store rankings within days of launch.</li>
</ul>
These developments open the door for enterprises — including banks — to stop merely consuming AI and start building it.
<h1 class="wp-block-heading">Banking's Quiet AI Revolution</h1>
<a href="https://www.citigroup.com/global/news/press-release/2024/citi-publishes-new-report-ai-in-finance">According to a 2024 Citibank report</a>, up to 54% of banking roles could be impacted by AI. The sector's heavy reliance on manual workflows, compliance-heavy documentation and repetitive research makes it ripe for disruption.
So far, most large U.S. banks have opted to explore generative AI via partnerships rather than by developing their own infrastructure:
<ul>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has deployed tools for automating meeting notes and summarizing research, aimed at enhancing financial advisor productivity.</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) partnered with OpenAI to launch internal assistants for email and document drafting, all integrated into its secure Omni platform.</li>
<li>Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) built an internal hub to access specialized AI tools, with a focus on developer productivity and task-specific model optimization.</li>
<li>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) are focused on customer-facing AI, deploying chatbots in mobile banking apps to answer user queries and handle support.</li>
</ul>
<h1 class="wp-block-heading">Why Banks May Need to Build Their Own AI</h1>
With open-source AI infrastructure advancing rapidly, banks now have compelling reasons to develop internal models:
<h3 class="wp-block-heading">&#x1f510; Enhanced Data Security</h3>
By building proprietary LLMs, banks can maintain end-to-end control over sensitive data, reduce reliance on external vendors, and ensure compliance with strict regulatory requirements.
<h3 class="wp-block-heading">&#x1f4ca; Unlocking Proprietary Data Value</h3>
Banks are sitting on massive pools of transaction and behavioral data that could power competitive AI models. Training open-source models in-house offers a cost-effective way to turn this underutilized data into differentiated digital services.
<h3 class="wp-block-heading">&#x1f4b8; Monetization Potential</h3>
Custom bank-built AI can serve internal teams or be licensed externally. As demand rises for financial data integration, models trained on proprietary datasets could enable entirely new product lines or revenue channels.
<h1 class="wp-block-heading">The Strategic Fork in the Road</h1>
Banks are now faced with a strategic decision: continue outsourcing AI capabilities to tech firms — or invest in building their own. With massive IT budgets and uniquely rich data troves, financial institutions are well-positioned to become creators of infrastructure, not just users.
The road ahead is clear. As open-source AI evolves, banking giants that invest in their own models today may define the next era of financial services.
Read Next: •<a href="https://www.benzinga.com/25/04/44838028/us-bancorp-beats-q1-estimates-on-strength-in-noninterest-income-loan-growth-and-cost-discipline"> U.S. Bancorp Beats Q1 Estimates, CEO Says &#8216;Revenues Outpaced Expenses&#8217;</a> Photo: Shutterstock

Tech

BankGPT: Why Open-Source AI May Reshape Future Of Financial Services

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 19.34% on an annualized basis producing an average annual return of 33.37%. Currently, Natera has a market capitalization of $20.02 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $423.33 today based on a price of $148.08 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744926311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRA

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

Enterprise Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBTC#NASDAQ">EBTC</a>) reported quarterly earnings of $0.84 per share. This is a 21.74 percent increase over earnings of $0.69 per share from the same period last year.

Earnings

EBTC

Enterprise Bancorp Q1 EPS $0.84 Up From $0.69 YoY

WKEY

WISeKey FY24 EPS $(0.39) Up From $(0.51) YoY; Revenue $11.875M Down From $30.918M YoY

BV Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVFL#NASDAQ">BVFL</a>) reported quarterly earnings of $0.21 per share. This is a 12.5 percent decrease over earnings of $0.24 per share from the same period last year.

BVFL

BV Financial Q1 EPS $0.21 Down From $0.24 YoY

United Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBFO#NASDAQ">UBFO</a>) reported quarterly earnings of $0.16 per share. This is a 33.33 percent decrease over earnings of $0.24 per share from the same period last year. The company reported $13.66 million in sales this quarter. This is a 6.96 percent increase over sales of $12.77 million the same period last year.

UBFO

United Security Q1 EPS $0.16 Down From $0.24 YoY, Sales $13.66M Up From $12.77M YoY

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.96% on an annualized basis producing an average annual return of 12.55%. Currently, Danaher has a market capitalization of $133.67 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $326.41 today based on a price of $186.83 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744925426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Press Releases

Trip.com Group Limited Reports Unaudited Second Quarter and First Half of 2024 Financial Results

Entertainment

Trip.com Group Highlights Golden Week 2024 Travel Shifts: Chinese Tourists Explore Beyond Capitals and Lesser-Known Options

Trip.com Group Limited to Report Third Quarter of 2024 Financial Results on November 18, 2024 U.S. Time

Trip.com Group Limited Reports Unaudited Third Quarter of 2024 Financial Results

Trip.com Group Announces Changes in Board Composition

Trip.com Group Limited to Report Fourth Quarter and Full Year of 2024 Financial Results on February 24, 2025 U.S. Time

Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2024 Financial Results

Offerings

Baidu Announces Proposed Offering of Exchangeable Bonds

Baidu Announces Pricing of US$2 Billion Offering of Zero Coupon Exchangeable Bonds

Trip.com Group Filed 2024 Annual Report on Form 20-F

BIDU

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Despegar.com

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

InterContinental Hotels

Lindblad Expeditions Holdings Inc. - Common Stock

Lindblad Expeditions

Marriott International - Class A Common Stock

Marriott International

MakeMyTrip

Norwegian Cruise Line Holdings Ltd. Ordinary Shares

Norwegian Cruise Line

Royal Caribbean Cruises Ltd. Common Stock

Royal Caribbean Gr

Sabre

Soho House & Co Inc. Class A Common Stock

Soho House

Target Hospitality

Travel+Leisure

Marriott Vacations Worldwide Corporation Common Stock

Marriott Vacations

Viking Holdings

Wyndham Hotels & Resorts, Inc. Common Stock

Wyndham Hotels & Resorts

JP Morgan

Benchmark

Citigroup

Barclays

Macquarie

수요일(9일) 오후 도널드 트럼프 대통령이 미국의 무역 조치에 보복하지 않은 국가에 대한 <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noopener">추가 관세 90일 유예</a>를 발표했다. 이에 대형 중국 기업 주식을 추종하는 iShares China Large-Cap ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NASDAQ">FXI</a>)가 반등해 7% 상승 마감했다. 
하지만 트럼프의 중국 수입에 대한 125% 관세 발표는 미국-중국 긴장에 대한 투자자들의 우려를 더욱 키웠고, 대형 중국 주식의 성과는 주요 미국 지수에 비해 부진했다. 
알아두어야 할 사항: FXI는 대형 중국 주식에 대한 노출을 제공하는 ETF로, 알리바바 그룹 홀딩 리미티드 ADR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)을 포함한다. FXI는 수요일 오후 개선된 글로벌 무역 심리에 힘입어 상승했다.
그러나 중국이 여전히 트럼프 행정부의 무역 조치 확대의 <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noopener">직접적인 표적</a>이 되고 있다는 사실로 인해 ETF의 상승세는 둔화되었다. 트럼프 대통령이 중국산 수입품에 대한 125% 관세 인상을 동시에 선언하면서 미중 긴장 지속에 대한 투자자들의 우려가 강화되었다.
또한 중국 경제의 구조적 문제도 <a href="https://www.benzinga.com/markets/asia/25/04/44715261/from-bad-to-terrible-treasury-secretary-slams-beijings-retaliatory-tariffs-as-trump-trade-agenda-wipes-trillions" target="_blank" rel="noopener">중국 증시 전망을 계속 압박</a>하고 있다. 국내 성장 둔화, 주요 기술 기업에 대한 지속적인 규제 조사, 환율 변동성 등으로 인해 글로벌 투자자들은 더욱 신중한 자세를 취하고 있다. 
관세 유예로 단기적으로 안도감을 줄 수 있지만, 중국 증시의 시장 대비 저조한 성과는 중국의 경제 궤적과 긴장된 미국과의 관계에 대한 지속적인 우려를 반영한다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 가장 좋은 성과를 보인 대형주 10개는 다음과 같다.
<ol>
<li>옥타 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>): 회사가 <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why" target="_blank" rel="noreferrer noopener">예상보다 나은</a> 4분기 재무 실적을 발표하고, 여러 애널리스트가 <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">주식 평가를 상향 조정하고 목표주가를 올린</a> 후 24.26% 상승했다.</li>
<li>아르셀로미탈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>): 금과 은의 강세로 19.50% 상승했다.</li>
<li>ING 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ING#NYSE">ING</a>): 회사가 7,000만 유로 규모의 자사주 매입 프로그램을 발표한 후 16.98% 상승했다.</li>
<li>포스코 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKX#NYSE">PKX</a>): 전체 시장의 강세와 트럼프 대통령이 자동차 관세를 연기할 것이라는 보도로 인해 15.55% 상승했다.</li>
<li>모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): 스테판 반셀(Stephane Bancel) CEO가 주식 매입을 공개한 후 15.02% 상승했다.</li>
<li>엘빗 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>): 14.80% 상승했다.</li>
<li>BJ&#8217;s 홀세일 클럽 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>): 회사가 예상치를 상회하는 <a href="https://www.benzinga.com//node/44165337" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a>을 발표한 후 14.06% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정했다.</a></li>
<li>로켓 컴퍼니스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>): 12.64% 상승했다.</li>
<li>트립닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>): 중국이 2025년 GDP 성장 목표를 약 5%로 설정하고 경기 부양 조치를 발표했다고 보도한 후 12.61% 상승했다.</li>
<li>스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): 비트코인 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 <a href="https://www.benzinga.com//node/44138476" target="_blank" rel="noreferrer noopener">9만 달러에 가까워졌다</a>는 소식으로 12.43% 상승했다.</li>
</ol>
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

많은 국가가 2025년까지 지출을 줄이려고 노력하고 있지만, 주목할 만한 국가 중 한 곳은 바로 중국이다. 중국 정부는 침체된 경제를 부양하기 위해 일련의 경기 부양책을 약속해 왔으며, 지난주 은행 부문에 550억 달러(4,000억 위안) 이상을 투입하겠다고 발표하면서 이러한 금전적 약속 중 하나가 이행되었다.
관세 여부와 관계없이 오늘 소개하는 4가지 주식은 급등할 수 있다.
이번 자금 투입은 성장이 절실한 중국의 수요를 촉진하기 위한 광범위한 경기 부양책의 일환이다. 중국의 인플레이션은 2023년 초부터 거의 제로에 가까웠고, 생산자 물가는 실제로 2년 연속 하락했다.
미국의 소비자들은 2021년, 2022년, 2023년에 평균 4%가 넘는 CPI를 기록한 후 연간 0.2%의 인플레이션 수치를 환영할 수 있지만, 중국 경제는 어려움을 겪고 있으며 상하이종합지수(SSE)는 2022년 초부터 계속 정체되고 있다.
하지만 정부가 경기 부양책을 내놓으면서 투자자들이 다시 활기를 띠기 시작했고, 몇몇 대형 중국 기업이 직접적인 수혜자가 될 수 있다.
오늘은 중국 정부의 경기 부양책의 수혜를 받을 수 있는 미국 상장 중국 기업 4곳을 살펴보고자 한다. 이 기업들은 대부분 대형주이지만 다양한 산업과 부문에 걸쳐 있다. 또한 이들 주식 중 일부는 2월 말 트럼프 행정부의 새로운 관세 위협 이후 주가가 하락했는데, 3월이 시작되면서 현명한 투자자에게는 매수 기회가 될 수 있다.
<h3 class="wp-block-heading">알리바바 그룹 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)</h3>
알리바바는 마침내 제대로 된 이유로 헤드라인을 장식하고 있다. 최근 실적 보고서는 애널리스트들로부터 수많은 투자의견 상향을 이끌어냈다. 중국 이커머스 대기업 알리바바는 2월 20일 보고서에서 매출 및 순이익 모두에서 예상치를 초과 발표하여 주가 상승을 이끌었고, 연초 대비(YTD) 50% 이상의 상승률을 기록했다. 특히 핵심 마켓플레이스 매출(CMR)과 AI가 접목된 알리클라우드(AliCloud) 부문과 같은 주요 영역에서 견고한 성장세를 보였다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154849/ali.png 1309w" alt="" width="1024" height="415" /></figure>
이러한 수치와 12월 중국 소매판매가 전년 대비 3.7% 증가했다는 점을 감안하면 알리바바 주가는 추가 상승의 발판을 마련한 것으로 보인다. 금요일에는 새로운 관세 위협으로 인해 주가가 하락했지만, 애널리스트들이 등급과 목표주가를 상향 조정하면서 강세 기조가 강화되었다.
2월 20일 실적 보고서가 나온 후 번스타인과 모건스탠리는 즉시 보유에서 매수 의견으로 상향 조정했고, JP모건, BofA 증권, 바클레이즈, 벤치마크의 애널리스트들 역시 모두 목표주가를 올렸다. 새로운 목표주가 중 가장 낮은 가격(150달러)은 2월 28일 종가 대비 12.6%의 상승 여력이 있음을 의미한다.
<h3 class="wp-block-heading">트립닷컴 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)</h3>
중국의 엄격한 코로나19 제한 조치로 여행 수요가 위축되었지만, 트립닷컴은 코로나19에 대해 알기 훨씬 전부터 어려움을 겪고 있었다. 2017년 7월 주가는 사상 최고치를 기록한 후 이후 5년 동안 꾸준히 하락했다. 2022년 10월에는 2014년 수준으로 급락했고, 2022회계연도에는 상당한 손실을 기록할 것으로 예상되었다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154856/tri.png 1309w" alt="" width="1024" height="415" /></figure>
그러나 트립닷컴 주가는 2022년 마지막 몇 달 동안 턴어라운드하기 시작했다. 2023년의 고르지 못한 주가 흐름 이후, 2024년에 주가가 급등하여 7년 만에 사상 최고치를 기록했다. 트립닷컴 주가는 2025년을 시작하며 하락세로 돌아섰고, 불과 몇 주 만에 77달러에서 56달러로 떨어졌다.
하지만 이러한 하락은 투자자들에게는 기회가 될 수 있다. 트립닷컴은 부채가 적고 수익의 16배에 불과한 주가로 거래되고 있다. 최근 2024년 4분기 실적에서 매출과 순이익 모두 예상치를 초과했다. 벤치마크와 JP모건은 각각 80달러와 75달러의 목표주가를 제시하고 매수 의견을 반복했다. 75달러는 현재 수준에서 거의 28% 상승 여력이 있는 가격이다.
기술적 관점에서 볼 때 상대강도지수(RSI)가 주요 임계치인 30까지 계속 하락함에 따라 곧 과매도 신호를 유발할 수 있다.
<h3 class="wp-block-heading">핀볼루션 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>)</h3>
핀볼루션 그룹은 시가총액이 21억 4,000만 달러에 불과해 이 목록에서 가장 작은 주식이다. 하지만 다른 종목들과 마찬가지로 오랜 고군분투 끝에 2024년에 부활의 조짐을 보였다. 핀볼루션은 온라인 마켓플레이스를 통해 소비자와 대출자를 연결하는 데 중점을 둔 핀테크 기업이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154903/inv.png 1309w" alt="" width="1024" height="415" /></figure>
핀볼루션 주가는 2021년 밈 주식 열풍이 불었을 때 단 3개월 만에 2달러 미만에서 8달러 이상으로 급등하며 큰 화제를 모았다. 하지만 대부분의 밈 주식과 마찬가지로 FINV도 2022년 3월에는 열풍 이전 수준으로 돌아갔다. 오늘날 주가는 소매업의 광풍이 아닌 진정한 성장 덕분에 주당 8달러에 가까운 가격으로 다시 거래되고 있다.
핀볼루션은 지난 12개월 동안 주당순이익이 12% 이상 성장했지만, 여전히 순방향 주가수익비율 5.65, 주가순자산비율 0.58로 수익의 7배에 불과한 수준에서 거래되고 있다. 핀볼루션은 2025년에 EPS가 13% 이상 성장할 것으로 예상하고 있으며, 주가는 이미 2025년에 21% 이상 상승했다. 시가총액이 작기 때문에 애널리스트의 커버리지는 적지만 펀더멘털과 기술적 신호 모두 앞으로 더 많은 잠재적 이익을 가리킨다.
<h3 class="wp-block-heading">JD닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)</h3>
알리바바닷컴이 타사 구매자와 판매자를 위한 비즈니스 마켓플레이스라면 JD닷컴은 중국판 아마존에 가깝다. JD닷컴은 세계에서 가장 광범위한 이커머스 운영과 고품질 제품 및 고객 서비스로 명성을 얻고 있다. 600억 달러의 시가총액은 알리바바의 3,150억 달러에 비하면 미미한 수준이지만, JD닷컴은 인상적인 수익 성장에도 불구하고 여전히 저평가되어 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-806849" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-1024x415.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/03154911/jD.png 1309w" alt="" width="1024" height="415" /></figure>
JD닷컴 주가는 2021년 초에 정점을 찍은 후 급격한 하락을 경험했다. 2021년 1월에 100달러를 돌파한 주가는 2024년 1분기 초에 22달러 아래로 급락했다. 80% 하락은 위험 감수성이 높은 투자자도 겁을 먹기에 충분하지만, 작년에 회사가 안정화되면서 주가는 반등하기 시작했다. JD닷컴은 최근 4분기 동안 1,563억 3,000만 달러의 매출을 올렸으며, 이는 이전 4분기보다 3% 증가한 수치다.
JD닷컴은 3월 6일에 2024년 4분기 실적을 발표할 예정이며, 애널리스트들은 코로나19 사태 이후 최고치인 450억 달러의 매출을 예상하고 있다. 바클레이즈는 2월 28일 보고서를 앞두고 목표주가를 50달러에서 55달러로 상향 조정했는데, 이는 현재 시장 가격 대비 24% 높은 수준이다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주에 가장 저조한 성과를 보인 12개의 대형주는 다음과 같다.
<ol>
<li>슈퍼마이크로컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): 회사의 분기 보고서가 미국 <a href="https://www.benzinga.com//node/44046734" target="_blank" rel="noreferrer noopener">증권거래위원회</a>에 제출된 후 지속적인 변동성으로 인해 26.06% 하락했다.</li>
<li>앱러빈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): <a href="https://www.benzinga.com//node/43981217" target="_blank" rel="noreferrer noopener">주식에 대한 여러 개의 공매도 보고서</a>가 발표된 후 21.57% 하락했다.</li>
<li>메이플베어 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>): 4분기 매출이 예상보다 저조하게 나타나고 애널리스트들이 <a href="https://www.benzinga.com//node/43985818" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>한 후 21.53% 하락했다.</li>
<li>넷앱 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>): 회사가 예상보다 저조한 3분기 매출 결과를 발표하고 4분기 및 2025회계연도 <a href="https://www.benzinga.com//node/44024261" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 발표한</a> 후 19.81% 급락했다.</li>
<li>퓨어 스토리지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>): 회사가 2026회계연도 <a href="https://www.benzinga.com//node/43989517" target="_blank" rel="noreferrer noopener">매출 가이던스를 예상보다 저조하게 발표</a>한 후 19.36% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 수정했다</a>.</li>
<li>듀오링고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): 엇갈린 4분기 결과를 발표한 후 19.02% 하락다. <a href="https://www.benzinga.com//node/44047945" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 전망을 수정했다.</a></li>
<li>비아트리스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>): 회사가 4분기 EPS와 매출이 예상보다 저조하게 나타나고 2026회계연도 매출 및 <a href="https://www.benzinga.com//node/44019622" target="_blank" rel="noreferrer noopener">및 EPS 가이던스도 예상보다 저조하게 발표한</a> 후 17.96% 하락했다. 뱅크오브아메리카증권 애널리스트 제이슨 게버리(Jason Gerberry)는 시장수익률 하회 의견을 유지하고 <a href="https://www.benzinga.com/quote/vtrs/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 11달러에 10달러로 하향 조정했다.</a></li>
<li>셈프라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>): 회사가 4분기 결과를 발표하고 전망을 하향 조정한 후 17.83% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43984834" target="_blank" rel="noreferrer noopener">목표주가를 수정했다</a>.</li>
<li>팔란티어 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 지난주 보도에서 트럼프 행정부가 <a href="https://www.benzinga.com//node/44032909" target="_blank" rel="noreferrer noopener">국방부에 예산 삭감을 계획하라고 지시했다</a>고 제시한 후 지속적인 약세가 우려되어 16.21% 하락했다.</li>
<li>트립닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>): 4분기 재무 결과를 발표한 후 15.43% 하락했다.</li>
<li>스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com//node/44037042" target="_blank" rel="noreferrer noopener">가격 하락</a> 이후 14.77% 급락했다.</li>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 회사가 1월에 유럽엽합에서 새로운 자동차 등록이 감소한 <a href="https://www.benzinga.com//node/43934934" target="_blank" rel="noreferrer noopener">보고서를 발표한</a> 후 13.27% 하락했다. 이는 매그니피센트 7 종목 중 <a href="https://www.benzinga.com//node/44043021" target="_blank" rel="noreferrer noopener">거의 유일한 급락세를 보인 주식</a>이다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CART

DUOL

NTAP

PLTR

PSTG

SMCI

TSLA

VTRS

테슬라·팔란티어·스트레티지 등 지난주 급락한 대형주 12종목 (2월 24일~28일)

화요일(25일) 아침 미국 주식 선물 가격이 하락하는 가운데 투자자들의 관심을 끌 수 있는 주식은 다음과 같다.
<ul>
<li>홈디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>): 오늘 개장 전 실적을 발표할 예정이다. 월가는 주당순이익 3.04달러, 매출 39억 700억 달러를 예상한다. 주식은 애프터마켓에서 1.2% 하락한 378.00달러에 거래되었다.</li>
<li>큐리그 닥터페퍼(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>): 오늘 개장 전 실적을 발표할 예정이다. 월가는 주당순이익 57센트, 매출 40억 달러를 예상하고 있다. 주식은 애프터마켓에서 0.4% 상승한 34.27달러에 거래되었다.</li>
<li>트립닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>): 월요일에 긍정적인 4분기 실적을 발표했다. 애프터마켓에서 주식은 0.4% 상승한 64.89달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>워크데이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>): 분기 주당순이익 1.78달러, 매출 21억 8천만 달러가 예상된다. 주식은 애프터마켓에서 0.4% 상승한 262.89달러에 거래되었다.</li>
<li>인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>): 분기 주당순이익 2.58달러, 매출 39억 3천만 달러가 예상된다. 주식은 애프터마켓에서 0.6% 상승한 570.80달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Pre-Market Outlook

WDAY

화요일 주목해야 할 주식: 홈디포, 큐리그 닥터페퍼, 트립닷컴, 워크데이 및 인튜이트

이들 9개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주가는 20.93% 급락했다. 공매도 업체인 힌덴버그 리서치의 비판적인 보고서는 <a href="https://www.benzinga.com//node/42784518" target="_blank" rel="noreferrer noopener">Carvana의 회복을 &#8220;신기루&#8221;</a>로 묘사하면서 약세 정서를 강화했다.
2. 소파이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)의 주식은 키프, 브루옛 &amp; 우즈(Keefe, Bruyette and Woods)가 <a href="https://www.benzinga.com/quote/SOfi/analyst-ratings" target="_blank" rel="noreferrer noopener">시장 수행에서 언더퍼폼으로 하향 조정</a>한 후 10.60% 하락했다.
3. 얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주식은 10.40% 하락했다.
4. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 회사가 4분기 <a href="https://www.benzinga.com//node/42766117" target="_blank" rel="noreferrer noopener">생산 및 인도 수치</a>를 발표한 후 9.62% 급락했다. 애널리스트들은 주식에 대한 <a href="https://www.benzinga.com//node/42786667" target="_blank" rel="noreferrer noopener">가격 예측</a>을 수정했다.
5. 킨세일 캐피털 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>)의 주식은 JP 모건이 주식의 목표 가격을 <a href="https://www.benzinga.com/quote/knsl/analyst-ratings" target="_blank" rel="noreferrer noopener">$415에서 $412로 하향 조정</a>한 후 9.45% 하락했다.
6. 브라운 포먼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>)의 주식은 미국 총기 건강 책임자 머시가 알코올 소비가 암 위험을 증가시킬 수 있다는 경고를 발표한 후 8.20% 하락했다.
7. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 씨티그룹이 주식의 가격 예측을 <a href="https://www.benzinga.com/quote/tcom/analyst-ratings" target="_blank" rel="noreferrer noopener">$73에서 $78로 상향 조정</a>한 후 7.47% 하락했다.
8. 포멘토 이코노미코 멕시카노 S.A.B. de C.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>)의 주식은 미국 공중보건국장인 비벡 머시(Vivek Murthy)가 알코올 소비와 관련된 암 위험 증가에 대해 경고한 후 7.47% 하락했다.
9. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주식은 9.47% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%AA%A8%EB%B9%8C%EC%95%84%EC%9D%B4-%EB%B0%8F-arm%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">리비안, 모빌아이 및 Arm은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 30일-1월 3일)</a></li>
</ul>
이미지 출처: Tesla
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

BF/B

CVNA

KNSL

SOFI

YUMC

테슬라, 소파이 및 주류 주식이 지난주 최악의 성과를 보인 9개 대형주 중 일부 (12월 30일-1월 3일)

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 더 하락했음을 나타내면서 지난 금요일에 &#8216;중립&#8217; 영역으로 이동했다.
금요일(15일) 미국 증시는 다우존스 지수가 장중 300포인트 이상 하락하는 등 하락세로 마감했다. S&amp;P 500 지수는 주간 2.1%의 손실을 기록했고, 나스닥 종합 지수는 3.2% 정도 하락했다. 30개 종목으로 구성된 다우존스 지수는 한 주 동안 1.2% 하락했다.
주요 기술주들은 손실을 기록했으며, 특히 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 주가는 금요일에 3% 이상 하락했고, 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 주가는 세션 중 약 2.8% 하락했다. 그러나 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 금요일에 약 3% 상승했다.
제약주는 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 임명한 후 금요일 하락세로 마감했다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) 주가는 7% 이상 하락했고 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) 주가도 4% 이상 하락했다. SPDR S&amp;P 바이오테크 ETF는 5% 이상 하락하며 2020년 이후 최악의 한 주를 기록했다.
경제 데이터 측면에서 10월 미국 수출 가격은 전월 대비 0.8% 상승했고, 10월 수입 가격은 전월 대비 0.3% 상승했다. 10월 미국 소매판매는 전월 대비 0.4% 증가하여 9월 수정치 0.8%보다는 하락했고, 시장 예상치 0.3%는 상회했다.
정보 기술, 통신 서비스, 헬스케어 섹터가 금요일에 가장 큰 손실을 기록하면서 S&amp;P 500의 대부분의 업종이 마이너스로 마감했다. 그러나 유틸리티와 금융 섹터는 전체 시장 추세와 다르게 상승세로 마감했다.
금요일 다우존스 지수는 약 306포인트 하락한 43,444.99포인트로 마감했다. S&amp;P 500 지수는 1.32% 하락한 5,870.62포인트, 나스닥 종합지수는 2.24% 하락한 18,680.12포인트로 마감했다.
투자자들은 오늘 트립닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), 브래디 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), 에이컴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란? </h3>
CNN 공포·탐욕 지수는 현재 50.9를 기록하고 있다. 금요일에 &#8216;탐욕&#8217;에서 &#8216;중립&#8217; 영역으로 이동했으며, 이전 수치는 58.2였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%ED%95%B4%EC%95%BC-%ED%95%A0-%EC%A3%BC%EC%8B%9D-%EB%B8%8C%EB%9E%98%EB%94%94-%EC%97%90%EC%9D%B4%EC%BB%B4-it-%ED%85%8C%ED%81%AC-%ED%8C%A8%ED%82%A4/" target="_blank" rel="noopener">월요일 주목해야 할 주식: 브래디, 에이컴, IT 테크 패키징, 빗디어 및 트립닷컴</a>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AMGN

MSFT

NVDA

美 경제지표 발표, 엔비디아와 MS 주가 하락 후 다우 지수 300p 이상 하락: 공포·탐욕 지수는 '중립'

월요일(18알) 아침에 미국 주식 선물이 혼조세를 보이고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다.
1. 브래디 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>)
<a href="//pro.benzinga.com/dashboard"" target="_blank" rel="noopener">벤징가 프로</a> 데이터에 따르면 월가에서는 오늘 개장 전 실적을 발표하는 브래디 코퍼레이션의 매출은 3억 6,588만 달러, 주당순이익은 1.10달러로 예상한다. 주가는 시간외 거래서 0.2% 상승한 74.38달러에 거래되었다.
2. 에이컴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)
애널리스트들은 장 마감 후 실적을 발표할 에이컴이 41억 4,400만 달러의 매출에 주당순이익 1.24달러를 기록할 것으로 예상한다. 주가는 시간외 거래에서 0.1% 상승한 106.99달러를 기록했다.
3. IT 테크 패키징 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>)
IT 테크 패키징은 분기 주당순손실 20센트를 발표했고 작년과 동일한 수치였다. 매출은 전년 대비 약 59% 증가하여 2,508만 달러에 달했다. 주식은 시간외 거래에서 0.6% 하락한 0.2495달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 커버리지</a>를 확인하세요.
4. 빗디어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>)
오늘 개장 전 실적을 발표하는 빗디어 테크놀로지스는 주당순손실 10센트와 매출 7,885달러를 발표할 것으로 예상된다. 주가는 시간외 거래에서 1.1% 상승한 11.21달러에서 거래되었다.
5. 트립닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)
장 마감 후 실적을 발표할 트립닷컴의 주당순이익은 91센트, 매출은 22억 달러로 예상된다. 주가는 시간외 거래서 0.01% 하락한 59.48달러에서 거래되었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A3%BC%EA%B0%84-%EC%A3%BC%EC%9A%94-%EC%9D%B8%EA%B3%B5%EC%A7%80%EB%8A%A5-%EB%89%B4%EC%8A%A4-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EC%95%A0%ED%94%8C-%EA%B3%B5%EA%B8%89%EC%97%85%EC%B2%B4/" target="_blank" rel="noopener">주간 주요 인공지능 뉴스: 엔비디아·애플 공급업체들이 정책 변화에 대비, 일본의 AI 도약 등</a>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

BTDR

월요일 주목해야 할 주식: 브래디, 에이컴, IT 테크 패키징, 빗디어 및 트립닷컴

지난주, 중국 중앙은행이 은행의 지급준비율(RRR)을 50bp(베이시스 포인트) 또는 0.5%포인트 인하하기로 발표하면서 미국에 상장된 중국 기업들의 <a href="https://www.benzinga.com//node/41065178" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가가 전반적으로</a> 상승했다.
지난주 가장 좋은 성과를 보인 10개의 대형 주식이 있다. 여러분의 포트폴리오에 포함되어 있나요?
1. JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주식은 중국 인민은행이 은행들이 보유해야 하는 현금의 양을 줄이기로 발표하고 <a href="https://www.benzinga.com//node/41062614" target="_blank" rel="noreferrer noopener">부동산 시장 지원 계획</a>을 발표한 후 39.75% 급등했다.
2. KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주식은 중국이 부양책의 일환으로 최대 2,840억 달러의 국채를 발행할 것이라는 보도가 나온 후 39.18% 상승했다.
3. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 중국이 부양책의 일환으로 최대 2,840억 달러의 <a href="https://www.benzinga.com//node/41026720" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">국채를 발행할 것</a>이라는 보도가 나온 후 35.52% 상승했다.
4. 리버티 브로드밴드 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41015233" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">차터 커뮤니케이션즈</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>)의 특별위원회에 반대 제안을 전달했다고 발표한 후 31.74% 상승했다.
5. 염 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주식은 중국의 부책 발표로 인해 27.64% 상승했다.
6. H 월드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>)의 주식은 중국 주식의 핀 액션으로 인해 26.43% 상승했다.
7. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 중국 주식의 핀 액션으로 인해 지난 주 26.02% 상승했다.
8. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식은 정부의 부양책 발표로 인해 중국 주식의 랠리에 동참하면서 23.48% 상승했다.
9. 윈 리조트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>)의 주식은 모건 스탠리가 중립에서 비중 확대 등급으로 상향 조정하고 목표 주가를 97달러에서 104달러로 <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정</a>한 후 22.47% 상승했다.
10. 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)의 주식은 정부의 부양책 발표로 인해 중국 주식의 랠리에 동참하면서 21.95% 상승했다.
알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)와 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)도 지난주 중국 주식의 랠리에 동참하여 각각 20% 이상 상승했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EC%A0%9C%EB%84%A4%EB%A1%A0%EA%B3%BC-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">리제네론 파마, 슈퍼 마이크로 컴퓨터 및 글로벌 페이먼츠는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 23일-9월 27일)</a></li>
</ul>
Photo by Eric Prouzet on Unsplash
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Emerging Markets

BEKE

CHTR

HTHT

LBRDA

WYNN

중국 주식 우세 - JD닷컴과 PDD는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 23일-9월 27일)

중국의 최신 경제 부양책이 글로벌 시장에 큰 파장을 일으키고 있다. <a href="https://www.benzinga.com/topic/china" target="_blank" rel="noopener" data-google-interstitial="false">다음과 같은</a> 중국 인민은행(PBoC)의 대담한 일련의 조치에 따라 이루어졌다:
<ul>
<li>은행들의 지급준비율(RRR)을 대폭 인하</li>
<li>주요 환매조건부채권(레포, repo) 금리 인하</li>
</ul>
이에 따라 유동성 유입이 국가 금융시스템에 영향을 줄 것으로 예상된다. 목표? 경제에 약 1,400억 달러를 투입하고 성장을 촉진하기 위해 더 많은 대출을 장려한다.
이 뉴스 이후 약간의 변동성이 있었지만, 일부 미국에 상장된 중국 주식들은 여전히 애널리스트들이 선호하는 종목으로 남아 있다. 다음은 강한 상승 잠재력을 가진 3개의 대형주에 대한 분석입니다. 현재 모두 애널리스트들로부터 매수 등급을 받고 있다.
<h2 class="wp-block-heading">트립닷컴: 중국 여행 붐으로 42% 상승 준비 완료</h2>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-566103" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131636/Screenshot-2024-09-25-at-10.36.06-PM.png" sizes="(max-width: 681px) 100vw, 681px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131636/Screenshot-2024-09-25-at-10.36.06-PM.png 681w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131636/Screenshot-2024-09-25-at-10.36.06-PM-300x181.png 300w" alt="" width="681" height="412" /></figure>
출처: <a href="https://www.benzinga.com/report/TCOM">Benzinga 주식 보고서 &#8211; TCOM</a>
이 목록의 첫 번째는 중국 최대 온라인 여행사인 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)이다. 지난 1년 동안 주가는 43% 이상 급등했으며, 연초부터 현재까지 무려 44%의 놀라운 상승률을 기록했다.
분석가들은 중국의 여행 부문이 반등하고 있는 가운데 중국 내 여권 보급률이 여전히 낮은 상황에서 트립닷컴의 잠재력에 대해 특히 낙관하고 있다. 해외 여행이 증가함에 따라 트립닷컴은 더 높은 마진 성장을 보일 것으로 예상된다.
애널리스트들은 향후 12개월 동안 주가가 $56에서 $72 사이로 상승할 수 있으며, 평균 목표가가 $64로 예상하고 있다. 이는 인상적인 42.21%의 상승 잠재력을 나타낸다.
주가 움직임: 트립닷컴의 주식은 수요일 3.73% 하락한 $51.08에 마감되었다.
<h2 class="wp-block-heading">징둥닷컴: 전자상거래 지배력으로 37% 상승 기대</h2>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-566104" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131748/Screenshot-2024-09-25-at-10.35.47-PM.png" sizes="(max-width: 681px) 100vw, 681px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131748/Screenshot-2024-09-25-at-10.35.47-PM.png 681w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131748/Screenshot-2024-09-25-at-10.35.47-PM-300x181.png 300w" alt="" width="681" height="412" /></figure>
출처: <a href="https://www.benzinga.com/report/JD" target="_blank" rel="noreferrer noopener">Benzinga 주식 보고서 &#8211; JD</a>
다음은 중국 최고의 전자상거래 플랫폼 중 하나인 징둥닷컴(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JD">JD</a>)이다.
징둥닷컴(JD.com)의 강점은 광범위한 물류 및 이행 인프라에 있으며, 이는 올해 지금까지 22%의 상승을 이끌어냈다.
애널리스트들은 JD의 미래에 대해 낙관적이며, 주가가 $28에서 $47 사이로 예상되며, 평균 목표가가 $37.50로 제시하고 있다. 이는 향후 1년 동안 36.97%의 상승 잠재력을 시사하며, 또 다른 강력한 선택 종목으로 자리 잡고 있다.
주가 움직임: JD의 주식은 수요일 2.04% 하락한 $33.21에 마감되었다.
참고: <a href="https://www.benzinga.com//node/41005816">알리바바, AI 및 자율주행 진전을 위해 엔비디아와 파트너십 체결, 차트 긍정적 모멘텀 나타내어</a>
<h2 class="wp-block-heading">알리바바: 30% 상승을 노리는 전자 상거래 거인</h2>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-566106" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131921/Screenshot-2024-09-25-at-10.35.27-PM.png" sizes="(max-width: 681px) 100vw, 681px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131921/Screenshot-2024-09-25-at-10.35.27-PM.png 681w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25131921/Screenshot-2024-09-25-at-10.35.27-PM-300x181.png 300w" alt="" width="681" height="412" /></figure>
출처: <a href="https://www.benzinga.com/report/BABA" target="_blank" rel="noreferrer noopener">Benzinga 주식 보고서 &#8211; BABA</a>
마지막으로 소개할 종목은 글로벌 전자상거래 분야의 거대 기업인 알리바바 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>)이 있다.
알리바바는 최근 몇 년 동안 어려움에 직면해 있지만 온라인 마켓플레이스에서 클라우드 컴퓨팅에 이르기까지 다양한 비즈니스 운영이 계속해서 분석가들의 관심을 끌고 있다. 주식은 올해 들어 21% 상승했으며, 애널리스트들은 12개월 가격 목표 범위를 $85에서 $130으로 예상하고 평균 $107.50로 제시하고 있다. 이는 29.78%의 상승 여력을 시사하며, 알리바바를 안정적인 장기 투자 종목으로 만들어 준다.
주가 움직임: 알리바바의 주식은 수요일 1.78% 하락한 $95.46에 마감되었다.

다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com//node/41011343">중국의 부양책으로 기술 주식 상승, 자재 부문 상승, 엔비디아 급등: 시장을 움직이는 요인은?</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Trip.com Group

뉴스

에 대한 최신 뉴스 Trip.com Group (NASDAQ:TCOM) 주식

목요일, 4월 10, 2025

일요일, 3월 09, 2025

화요일, 3월 04, 2025

일요일, 3월 02, 2025

화요일, 2월 25, 2025

일요일, 1월 05, 2025

월요일, 11월 18, 2024

일요일, 9월 29, 2024

목요일, 9월 26, 2024

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌